Modus Therapeutics has announced the outcome of the exercise of warrants of series TO 2026, which were issued in connection with the rights issue in summer 2025. The exercise rate amounted to 94.8 per cent, providing the company with approximately SEK 9.5 million before issue costs.
KDventures, which owns 56 per cent of Modus Therapeutics directly and a further 2 per cent indirectly via KDev Investments, exercised its pro rata share in the warrant programme. The investment corresponds to approximately SEK 5.1 million.
The proceeds will be used to finance Modus Therapeutics’ continued clinical development of the drug candidate sevuparin, as well as to strengthen working capital and enable continued business development.
The drug candidate sevuparin is being evaluated in an ongoing Phase IIa clinical study in chronic kidney disease with anaemia, where the aim is to demonstrate proof of concept. In parallel, sevuparin is being developed as a potential treatment for sepsis and severe malaria.